Health ❯ Healthcare ❯ Vaccines ❯ mRNA Technology

Vaccine Development

FDA to Review Moderna’s Flu Shot as Shares Rally on Earnings Beat

The review sets a decision deadline of August 5, 2026, signaling progress in Moderna’s shift toward a seasonal vaccine strategy.

HHS Axes $500 Million in BARDA mRNA Vaccine Projects, Drawing Intensifying Warnings

Kennedy Halts $500 Million in mRNA Vaccine Contracts, Shifts Investment to Alternative Platforms